Search
Semaglutide Treatment Options for Obesity
A collection of 71 research studies in Obesity where Semaglutide is the interventional treatment. Semaglutide is used for conditions such as Obesity.
13 - 24 of 71
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Obesity
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
High Triglyceride Clinical Research Study
Recruiting
Living with high triglycerides? See if our clinical study is right for you.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Conditions:
High Triglycerides
High Triglyceride Level
Hypertriglyceridemia
Elevated Triglycerides
Triglycerides High
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
Enrolling By Invitation
The purpose of this research is to find out if an aggressive intervention to lose weight, will improve symptoms in patients with obesity-related cardiomyopathy, which is also known as the obese phenotype of heart failure with preserved ejection fraction (HFpEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity
ADJUnct Semaglutide Treatment in Type 1 Diabetes
Completed
The purpose of this study is to assess the use of once weekly semaglutide injection in inadequately controlled obese adults with type 1 diabetes (T1D) using FDA-approved hybrid closed-loop therapies.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/28/2025
Locations: Barbara Davis Center for Diabetes, Aurora, Colorado +3 locations
Conditions: Type 1 Diabetes, Obesity
Sit Less, Interact and Move More (SLIMM) 2 Study
Recruiting
* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death.
* In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained.
* Theref... Read More
Gender:
ALL
Ages:
20 years and above
Trial Updated:
03/28/2025
Locations: Stanford University, Stanford, California +1 locations
Conditions: Chronic Kidney Diseases, Obesity
Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
Active Not Recruiting
This study will evaluate the effect of semaglutide on eating behavior, appetite (hunger/fullness), and food liking in the long-term, as compared to placebo. All participants will receive lifestyle modification (diet and exercise) counseling, and will be prescribed the FDA-approved weight loss medication, semaglutide, or placebo (an inactive saline solution) for 72 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/24/2025
Locations: University of Pennsylvania Center for Weight and Eating Disorders, Philadelphia, Pennsylvania
Conditions: Obesity
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Recruiting
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to the 2 medicines semaglutide and cagrilintide, when they are taken alone. It will also compare CagriSema to a "dummy" medicine (also called placebo) without any active ingredient. Participant will either get CagriSema, se... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: John Muir Physicians Network, Concord, California +139 locations
Conditions: Chronic Kidney Disease, Type 2 Diabetes, Obesity
Feasibility of Semaglutide in Advanced Lung Disease
Recruiting
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease.
The main question\[s\] it aims to answer are:
1. Are patients with advanced lung disease able to tolerate semaglutide therapy?
2. Are we able to titrate semaglutide therapy to a target weight?
Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a bl... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/13/2025
Locations: University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo
Active Not Recruiting
This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/10/2025
Locations: Pinnacle Research Group, Anniston, Alabama +15 locations
Conditions: Obesity
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Active Not Recruiting
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +44 locations
Conditions: Obesity
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Recruiting
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Valley Clinical Trials, Covina, California +36 locations
Conditions: Obesity
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
Active Not Recruiting
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/27/2025
Locations: Pinnacle Research Group, LLC, Anniston, Alabama +25 locations
Conditions: Obesity, Obese, Overweight or Obesity
Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents
Recruiting
The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide) can help people 12 to 24 years old who, between 1 and 2 years after bariatric surgery, have not lost as much weight as expected.
Gender:
ALL
Ages:
Between 12 years and 24 years
Trial Updated:
02/24/2025
Locations: Childrens Hospital Colorado, Aurora, Colorado
Conditions: Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory, Bariatric Surgery, Anti-obesity Agents
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Active Not Recruiting
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Aurora FDRC Inc., Costa Mesa, California +23 locations
Conditions: Obesity
13 - 24 of 71